InvestorsHub Logo
Followers 8
Posts 1500
Boards Moderated 0
Alias Born 07/22/2013

Re: CATTDOGG12347 post# 79934

Friday, 09/07/2018 4:38:01 AM

Friday, September 07, 2018 4:38:01 AM

Post# of 108191
I’m pretty sure everyone here knew Dilution was coming it was enevitable! I saw this coming as you can see in my last few post. Her2 deal was just a booster to get share price above $1.50 a share for the offering. No way anyone here can say they didn’t know it was coming because they had no other choice! I’m fine at this time with it because it gives us some wiggle room as we wait for results with NEO and allows us a chance to continue on as a company. Advaxis has been beaten down at every turn and our Lm platform has shown great promise someone wants to take us over for nothing and I’m hoping Ken Berlin sees the light and is fighting to keep our hopes alive . This is no surprise and have been waiting for this time for a while now. Terrible management has been our Achilles heel at Advaxis. Hiring people for jobs we never needed to fill. Frivolous spending on poorly designed trials? Where do I stop? Poor Dr. Patterson has seen her Lm Therapy pretty much flopping like a fish out of water still breathing and alive but gasping for air at every turn lately. I promise she isn’t very happy with these BOZO’s we call Management and our BOD. Is Amgen slow playing us? These are the things we must ask the powers to be ? What was our milestone payment from Amgen on start of NEO trial? Company needs to be more transparent! This has to be a top priority of management to common shareholders. Allow us to make a informed decision on what the heck your trying to accomplish? Do you have a interested party in HOT like We do with NEO with Amgen or are we trying to do it our selves because that will take too much money for us to go it alone my friends what direction are we actually going with this? These are things we need to know.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News